Biopharmaceutical News and Research

RSS

Tranzyme Pharma receives BioQuébec's 2010 Genesis Award for "Innovation"

Tranzyme Pharma, a clinical-stage biopharmaceutical company, announced today that the Company has been awarded BioQuébec's 2010 Genesis Award for "Innovation", having demonstrated strong and proven innovation in the field of life sciences.

7 Jun 2010

Poniard reports positive data from Phase 3 SPEAR trial of picoplatin for SCLC

Poniard Pharmaceuticals, Inc., a biopharmaceutical company focused on innovative oncology therapies, today announced the full efficacy and safety data from its Phase 3 SPEAR (Study of Picoplatin Efficacy After Relapse) trial of picoplatin in the second-line treatment of small cell lung cancer (SCLC).

7 Jun 2010

OXiGENE presents updated data from ZYBRESTAT Phase 2 study in NSCLC at 2010 ASCO

OXiGENE, Inc., a clinical-stage, biopharmaceutical company developing novel therapeutics to treat cancer and eye diseases, announced today that it presented updated safety and clinical activity data from the FALCON trial, a randomized, controlled Phase 2 study of ZYBRESTAT™ (CA4P) in patients with non-small cell lung cancer (NSCLC), at the 2010 Annual Meeting of the American Society of Clinical Oncology (ASCO).

7 Jun 2010

Microplasmin exhibits potential to cure 50% of patients with macular hole

ThromboGenics NV, a biopharmaceutical company focused on the discovery and development of innovative treatments for eye disease, announces that further data from the first successful Phase III trial with microplasmin (TG-MV-006) for the non-surgical treatment of vitreomacular adhesion (VMA) were presented at the World Ophthalmology Congress by Dr. Matthew Benz, MD (The Methodist Hospital, Houston, Texas, U.S.)

7 Jun 2010

AVEO's initiation of SCH 900105 Phase 2 trial in non-small cell lung cancer triggers $8.5M milestone payment

AVEO Pharmaceuticals, Inc., a biopharmaceutical company focused on discovering, developing and commercializing cancer therapeutics, today announced that it has initiated a Phase 2 clinical trial evaluating SCH 900105 (also referred to as AV-299) for the treatment of non-small cell lung cancer. The initiation of this trial triggers an $8.5 million milestone payment by Merck to AVEO resulting from a 2007 agreement between AVEO and Schering-Plough (now Merck).

7 Jun 2010

Phase Ib/II trial data for trastuzumab-DM1 in combination with pertuzumab presented at ASCO 2010

ImmunoGen, Inc., a biopharmaceutical company that develops targeted anticancer therapeutics, today announced the presentation of clinical data from a Phase Ib/II trial conducted by Roche and Genentech to investigate the safety and preliminary efficacy of trastuzumab-DM1 (T-DM1) used in combination with Roche's investigational antibody, pertuzumab.

7 Jun 2010

Media increases effectiveness of direct-to-patient marketing approaches

All too often, study sponsors provide research sites with an advertising budget to promote their clinical trial to patients, and yet the majority of research sites require support or guidance on where and when to invest these advertising dollars. This support comes from trained and experienced advertising professionals who are experts in knowing the best way to maximize advertising budgets, and optimize the return on advertising investment.

5 Jun 2010

MediciGlobal survey identifies strategies followed in patient recruitment for clinical trials

Much is written about how patient recruitment can either accelerate or undermine clinical trial success. But how is the industry approaching patient recruitment in general? Do companies plan proactively? Who is involved in the process and what decisions do they make in order to effectively plan for success?

5 Jun 2010

BioSpecifics' board authorizes $2 million common stock repurchase program

BioSpecifics Technologies Corp., a biopharmaceutical company developing first in class collagenase-based products, today announced that its Board of Directors has authorized the repurchase of up to $2 million of its outstanding common stock. This decision reflects the Company's continued commitment to increasing value for its stockholders and its confidence that it will achieve its goals.

4 Jun 2010

Nuon Therapeutics' abstracts on tranilast against gout accepted for presentation at EULAR 2010

Nuon Therapeutics, Inc., a privately held, clinical stage biopharmaceutical company, announced that two scientific abstracts on the activity of tranilast against key components of gout - high serum uric acid levels and monosodium urate crystal-induced inflammation - have been accepted for The European League Against Rheumatism (EULAR) 2010 Annual European Congress of Rheumatology, to be held in Rome, Italy, June 16-19, 2010.

4 Jun 2010

Morria Biopharmaceuticals to present Phase II study results of MRX-4 at EAACI Congress

Morria Biopharmaceuticals Plc, a biopharmaceutical company focused on novel, anti-inflammatory drugs, announced today that it will be presenting the results from its ICH compliant Phase II study of MRX-4>th EAACI Congress in London on June 7th. The results will be presented by the study's principal investigator Prof. Eric Bateman.

4 Jun 2010

Royal Philips Electronics, RXi Pharmaceuticals sign joint research agreement

Royal Philips Electronics and RXi Pharmaceuticals Corporation, a US-based biopharmaceutical company, today announced that they have entered into a joint research agreement to explore the benefits of combining proprietary technologies from both companies for the targeted delivery of experimental therapeutics based on RNA interference.

4 Jun 2010

PregLem reports positive Phase III data from PEARL I study of Esmya for uterine fibroids

PregLem, the European specialty biopharmaceutical company focused on women's reproductive medicine, announces positive Phase III data from its second pivotal study (PEARL I) for its lead product Esmya (ulipristal acetate), as an effective treatment for uterine fibroids (myoma) - a condition that affects millions of women worldwide.

4 Jun 2010

MicroStockProfit.com releases investment report featuring Rexahn Pharmaceuticals

MicroStockProfit.com announces an investment report featuring Rexahn Pharmaceuticals Inc. The report includes financial, comparative and investment analyses, and industry information you need to know to make an educated investment decision.

3 Jun 2010

Constellation Pharmaceuticals raises $22 million in Series B financing round

Constellation Pharmaceuticals, Inc., the leading biopharmaceutical company focused on discovering and developing new drugs targeting epigenetic regulation of the human genome, today announced that it has raised $22 million in a Series B financing round.

2 Jun 2010

Santarus commences enrollment in rifamycin SV MMX Phase III clinical program for travelers' diarrhea

Santarus, Inc., a specialty biopharmaceutical company, today announced that is has begun to enroll patients in the first study in its Phase III clinical program to evaluate the efficacy and safety of rifamycin SV MMX® for the treatment of patients with travelers' diarrhea.

2 Jun 2010

FDA accepts Orexigen's Contrave NDA for treatment of obesity

Orexigen® Therapeutics, Inc., a biopharmaceutical company focused on the treatment of obesity, today announced that the U.S. Food and Drug Administration (FDA) has accepted for filing the Company's New Drug Application (NDA) for Contrave® (naltrexone SR/bupropion SR), its investigational drug for the treatment of obesity.

2 Jun 2010

Tetraphase Pharmaceuticals raises $45M in Series C financing

Tetraphase Pharmaceuticals, a clinical stage biopharmaceutical company utilizing breakthrough synthetic chemistry technology to discover and develop next-generation antibiotics, today announced that it has raised $45 million in a Series C financing.

2 Jun 2010

PAREXEL International establishes new brand identity "Right Where You Need Us"

PAREXEL International Corporation, a leading global biopharmaceutical services provider, today announced that it has established the new brand identity "Right Where You Need Us," which reflects various transformation initiatives focused on meeting the diverse requirements of the Company's clients.

From Parexel 1 Jun 2010

MediSapiens completes $1M seed round investment for personalized cancer medicine software

MediSapiens, world's first software company for personalized cancer medicine in oncology clinics and drug development, completed $ 1 million (EUR 0.8 million) seed round investment from Veraventure, ETFIII advised by Eqvitec Partners, VTT Ventures and Lifeline Ventures.

1 Jun 2010

Biopharmaceutical News and Research

Tranzyme Pharma receives BioQuébec's 2010 Genesis Award for "Innovation"

Poniard reports positive data from Phase 3 SPEAR trial of picoplatin for SCLC

OXiGENE presents updated data from ZYBRESTAT Phase 2 study in NSCLC at 2010 ASCO

Microplasmin exhibits potential to cure 50% of patients with macular hole

AVEO's initiation of SCH 900105 Phase 2 trial in non-small cell lung cancer triggers $8.5M milestone payment

Phase Ib/II trial data for trastuzumab-DM1 in combination with pertuzumab presented at ASCO 2010

Media increases effectiveness of direct-to-patient marketing approaches

MediciGlobal survey identifies strategies followed in patient recruitment for clinical trials

BioSpecifics' board authorizes $2 million common stock repurchase program

Nuon Therapeutics' abstracts on tranilast against gout accepted for presentation at EULAR 2010

Morria Biopharmaceuticals to present Phase II study results of MRX-4 at EAACI Congress

Royal Philips Electronics, RXi Pharmaceuticals sign joint research agreement

PregLem reports positive Phase III data from PEARL I study of Esmya for uterine fibroids

MicroStockProfit.com releases investment report featuring Rexahn Pharmaceuticals

Constellation Pharmaceuticals raises $22 million in Series B financing round

Santarus commences enrollment in rifamycin SV MMX Phase III clinical program for travelers' diarrhea

FDA accepts Orexigen's Contrave NDA for treatment of obesity

Tetraphase Pharmaceuticals raises $45M in Series C financing

PAREXEL International establishes new brand identity "Right Where You Need Us"

MediSapiens completes $1M seed round investment for personalized cancer medicine software

eBook: Using iPSCs models for human disease research and drug discovery eBook

Advancing Intracellular Delivery with LumiPore®

How ELRIG Is Helping Mid-Career Scientists Navigate Leadership, Career Change and Redundancy

The role of UV-Vis in biopharma QC

Latest News